Streetbeat News

Price Targets

VRTX

Cantor Fitzgerald analyst Olivia Brayer has reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $380.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:34 pm

WLK

Westlake's stock (WLK) is trading higher following UBS's decision to maintain a Neutral rating but increase the price target from $127 to $139.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:32 pm

ALNY

Cantor Fitzgerald analyst Olivia Brayer has reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $165. The reaffirmation of the Neutral stance and price target suggests that the analyst sees the stock trading around current levels in the near term.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:31 pm

ACAD

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintained a $42 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:30 pm

ITCI

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a price target of $101.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:26 pm

LFMD

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on LifeMD (NASDAQ: LFMD) and maintained a $9 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:13 pm

BIRD

Piper Sandler analyst Edward Yruma has maintained a Neutral rating on Allbirds (NASDAQ:BIRD) and reduced the price target from $1.8 to $1.6.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:10 pm

AMAT

Applied Materials' stock (AMAT) is trading higher following an increase in price target from $165 to $185 by TD Cowen.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:07 pm

ALNY

Piper Sandler analyst Edward Tenthoff has maintained an Overweight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and increased the price target from $210 to $217.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:07 pm

TXG

10x Genomics' stock (TXG) is experiencing an uptick after Guggenheim initiated coverage with a Buy rating and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 5:06 pm